Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Mar 24, 2021 2:59pm
81 Views
Post# 32868134

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:First Patient Dosed in Phase 1 Trial of TH1902

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:First Patient Dosed in Phase 1 Trial of TH1902

I don't think THTX are doing anything different to what most serious biotech do, this is the tradional way to approach much of the science stuff. The science stuff while important usually doesn't speak directly to commercial milestones so usually it is of less significance and therefore requires no fanfare. It is odd to me that repeatedly the stock responds to the science data and not to any of the more concrete commercial milestones, I think this is exuberant trading on data that most people struggle to understand. While it's exciting to watch as a shareholder I'm not sure all this SP action has much relevance to the long term health of the company or stock, they need to impress the market in the more traditional ways and have that impactful. It wouldn't surprise me if today's action is part of the hangover from Monday's frenzy as anything to do with today's PR.
 


scarlet1967 wrote: Isn't this "milestone", Dr. Stanley's sub analysis even(not posted on the website) AACR abstracts worth a CC?


 

<< Previous
Bullboard Posts
Next >>